Abstract

This phase 2 trial involving patients with NASH showed that treatment with semaglutide resulted in a significantly higher percentage of patients with NASH resolution than placebo. However, the trial did not show a significant between-group difference in the percentage of patients with an improvement in fibrosis stage. (Funded by Novo Nordisk; ClinicalTrials.gov number, NCT02970942.).

Keywords

SemaglutideNonalcoholic steatohepatitisMedicinePlaceboInternal medicineSteatohepatitisGastroenterologyDiabetes mellitusLiraglutideEndocrinologyType 2 diabetesAlternative medicineNonalcoholic fatty liver diseaseFatty liverPathology

MeSH Terms

AdolescentAdultAgedAmylasesBiopsyDiabetes MellitusType 2Dose-Response RelationshipDrugDouble-Blind MethodFemaleGlucagon-Like PeptidesHumansInjectionsSubcutaneousLipaseLiverLiver CirrhosisMaleMiddle AgedNon-alcoholic Fatty Liver DiseaseYoung Adult

Affiliated Institutions

Related Publications

Nonalcoholic Steatohepatitis

Elizabeth M. Brunt

Nonalcoholic fatty liver disease (NAFLD) is being increasingly recognized as a common liver disorder that represents the hepatic manifestation of the metabolic syndrome, a varia...

2004 Seminars in Liver Disease 477 citations

Publication Info

Year
2020
Type
article
Volume
384
Issue
12
Pages
1113-1124
Citations
1648
Access
Closed

External Links

Download PDF (Free) View on DOI.org PubMed Semantic Scholar

Social Impact

Altmetric
PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

1648
OpenAlex
89
Influential
1544
CrossRef

Cite This

Philip N. Newsome, Kristine Buchholtz, Kenneth Cusi et al. (2020). A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis. New England Journal of Medicine , 384 (12) , 1113-1124. https://doi.org/10.1056/nejmoa2028395

Identifiers

DOI
10.1056/nejmoa2028395
PMID
33185364

Data Quality

Data completeness: 90%